Det er ikkje nok å berre løfta ein - alle må løftast i Yrkesfaglærarløftet

Figure S1. Western blots showing that the reduction in RAD51 levels after cisplatin treatment in melanoma cells is not seen in other cell types. Blots support the RAD51 quantification shown in Fig. 2 of the main text. Figure S2. Images showing that RAD51 repair foci are not induced by short term cisplatin treatment of melanoma cells. Figure S3. The cisplatin-induced reduction in RAD51 levels in melanoma cells is not affected by proteasome or lysosome inhibitor treatment. Figure S4. Melanoma cells show only a weak cisplatin-induced G2 arrest. Figure S5. Specificity of antibodies to translesion synthesis DNA Polymerases. Figure S6. Western blots showing increased levels of DNA Polymerase zeta in cisplatin-treated melanoma cells. Blots support the DNA Pol ζ and Pol η expression data shown in Fig. 7 of the main text. (PDF 2393 kb